NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Canopy Growth Corporation ("Canopy Growth") (NASDAQ:CGC) concerning possible violations of federal securities laws. On February 7, 2025, Canopy issued a press release on the Company's financial results for the third quarter of its fiscal year 2025.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Triumph Financial, Inc. ("Triumph Financial, Inc.") (NASDAQ:TFIN) concerning possible violations of federal securities laws. On January 22, 2025, after market close, Triumph published a quarterly earnings report stating that it had a profit of $0.13 per share, missing the Zacks Consensus Estimate of $0.26 per share by 50%.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Oscar Health, Inc. ("Oscar Health, Inc.") (NYSE:OSCR) concerning possible violations of federal securities laws. Oscar Health reported mixed earnings performance for the fourth quarter including a greater than expected loss of $0.62 per share.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ePlus inc. ("ePlus inc.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agilysys, Inc. ("Agilysys, Inc.") (NASDAQ:AGYS) concerning possible violations of federal securities laws. On January 21, 2025, Agilysys issued a press release announcing third quarter revenue below expectations and the company's own guidance, resulting in a significant revision to Agilysys' FY25 revenue guidance.

I've been investing in Chemours for years, despite recent accounting irregularities and share price decline since before 2024. Chemours, a leader in the titanium dioxide sector, also excels in new refrigerants like Opteon due to regulatory changes. Despite recent poor returns, I remain confident in Chemours' fundamentals and long-term potential, especially after 4Q24.

We're harnessing the power of AI to provide interactive, real-time support that helps developers create better software, more quickly and with less hassle.

Revenue of more than $2.4 billion, with sequential growth in Industrial, Automotive, and Communications, and double-digit year-over-year growth in Consumer Operating cash flow of $3.8 billion and free cash flow of $3.2 billion on a trailing twelve-month basis Raised quarterly dividend 8% to $0.99, marking twenty-one consecutive years of increases Increased share repurchase authorization by $10.0 billion, bringing total remaining authorization to approximately $11.5 billion WILMINGTON, Mass. , Feb. 19, 2025 /PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI), a global semiconductor leader, today announced financial results for its fiscal first quarter 2025, which ended February 1, 2025.

While Starbucks Co. NASDAQ: SBUX captured headlines in 2024 under former Chipotle Mexican Grill Inc.'s NYSE: CMG superstar CEO Brian Niccol's turnaround efforts, Dutch Bros Inc. NYSE: BROS has been quietly outperforming, delivering double the returns. Dutch Bros stock is up 56% year-to-date (YTD), far surpassing Starbucks' 24% YTD gain, as of Feb. 14, 2025, and it just reported another quarter of hypergrowth with revenues surging 35% year-over-year (YoY).

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edison International ("Edison" or "the Company") (NYSE:EIX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Edison securities between February 25, 2021 and February 6, 2025, both dates inclusive (the "Class Period").

Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential impact across a range of tumors //Republication of press release issued February 18 th 2025 due to news transmission coverage// SAN DIEGO and CALGARY, AB , Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments …

Deployments of Cyngn's DriveMod Tugger and Forklift have now included four key sectors: Manufacturing, Consumer Packaged Goods, Logistics, and Defense Use cases are diverse and highlight adaptability, scalability, and different value propositions of Cyngn's solutions. Reflects market demand to adopt industrial automation across Cyngn's broadening customer base.

Toronto, Ontario--(Newsfile Corp. - February 19, 2025) - C3 Metals Inc. (TSXV: CCCM) (OTCQB: CUAUF) ("C3 Metals" or the "Company") is pleased to announce results of a highly successful grid-based soil sampling campaign over the Khaleesi Copper-Gold project area in Southern Peru. Previous mapping and rock sampling identified an alteration footprint spanning 1,500m by 1,000m.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").

- PDUFA target action date of Aug. 19, 2025 - WARREN, N.J. , Feb. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for vatiquinone for the treatment of children and adults living with Friedreich's ataxia (FA).

Highest-ever quarterly revenue achieved in Q4 24 BROOKLYN, N.Y. , Feb. 19, 2025 /PRNewswire/ -- Etsy, Inc. (NASDAQ: ETSY), which operates two-sided online marketplaces that connect millions of passionate and creative buyers and sellers around the world, today announced financial results for its fourth quarter and full year ended December 31, 2024.

Dallas, Texas--(Newsfile Corp. - February 19, 2025) - enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the “Company” or “enCore”), America's Clean Energy Company™, is pleased to announce its participation at the upcoming Prospectors & Developers Association of Canada's (PDAC) Convention at the Metro Toronto Convention Centre (MTCC) from Sunday, March 2 to Wednesday, March 5, 2025. Attendees can meet with enCore Energy team members at Booth #3028 in the Investor's Exchange.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against FTAI Aviation Ltd. ("FTAI Aviation" or "the Company") (NASDAQ:FTAI) and certain of its officers.

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nextracker Inc. ("Nextracker" or "the Company") (NASDAQ: NXT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nextracker securities between February 1, 2024 and August 1, 2024, both dates inclusive (the "Class Period").